Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience-ROSE Korea Study.

Sci Rep · 2026 · PMC12859025 · PMID 41513729

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendP = 0.06so close (0.05 < p ≤ 0.1)

Baseline visual acuity was similar between groups (0.6 ± 0.6 vs 0.6 ± 0.6 logMAR, P = 0.92), while central macular thickness showed a trend toward difference (368.7 ± 172.0 vs 398.0 ± 169.4 μm, P = 0.06) (Table 1 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.